Skip to main content
Search

# GeoFlow V4

1 related articles

Subscribe to updates
  1. BioGeometry releases GeoFlow V4: 34.6% average experimental hit rate across 15 de novo design tasks, about 85% above the previous generation

    BioGeometry released GeoFlow V4, a new-generation drug discovery engine that reaches a project-level average experimental hit rate of 34.6% across 15 de novo design tasks spanning 13 disease-relevant targets, about 85% higher than the previous generation, with top affinity about 100-fold improved. The release designs small proteins, cyclic peptides, nanobodies and IgG antibodies de novo within one framework, and adds GeoFlow Code, an agentic design-orchestration system that turns multi-round design into executable, adjustable workflows. On a cross-species PD-1 IgG design task, GeoFlow Code's self-orchestrated pipeline reached a 4.23% overall pass rate versus 0.16% for the expert-planned pipeline.

You’re all caught up